177Lu-PSMA Articles

Articles

  • External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.

    Prostate-specific membrane antigen (PSMA)-targeted therapy with 177Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiation protection and safety necessities.

    Published April 17, 2018
  • PSMA Theranostics: Current Status and Future Directions.

    Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177Lu-labeled PSMA ligands.

    Published June 15, 2018